Share:
A blog by Dr Fiona Creswell
Dr Fiona Creswell, a physician and clinical researcher at the MRC/UVRI & LSHTM Uganda Research Unit, explores what the IMPALA trial tells us about the potential of long-acting HIV treatment in Africa, and why affordability, access and health-system readiness will be critical to ensuring that the people who need it most can benefit.
Read the full blog here.
Related HIV and Co-Infections News
-
[IDWeek 2026] Contagion Live | Asuptegravir lowers HIV-1 RNA up to 2.36 logs in early monotherapy
-
[IDWeek 2026] Infectious Disease Advisor | Novel doravirine/islatravir yields similar patient-reported outcomes in HIV-1
-
[IDWeek 2026] Infectious Disease Advisor | Bictegravir/lenacapavir well tolerated in people with HIV and comorbidities
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.